These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34817825)

  • 1. Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients.
    Jung EH; Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Choi CI; Jang CG; Lee SY
    Arch Pharm Res; 2021 Dec; 44(12):1109-1119. PubMed ID: 34817825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
    Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.
    Choi CI; Kim MJ; Chung EK; Lee HI; Jang CG; Bae JW; Lee SY
    Eur J Clin Pharmacol; 2012 Feb; 68(2):149-54. PubMed ID: 21842338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
    Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
    J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype.
    Uchida S; Watanabe H; Nishio S; Hashimoto H; Yamazaki K; Hayashi H; Ohashi K
    Clin Pharmacol Ther; 2003 Nov; 74(5):505-8. PubMed ID: 14586391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.
    Hong X; Zhang S; Mao G; Jiang S; Zhang Y; Yu Y; Tang G; Xing H; Xu X
    Eur J Clin Pharmacol; 2005 Oct; 61(9):627-34. PubMed ID: 16094537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide.
    Aberg JG; Olofsson B; Karlson BW
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):750-5. PubMed ID: 22122817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.
    Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Choi CI
    Arch Pharm Res; 2023 Dec; 46(11-12):939-953. PubMed ID: 38064121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
    Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
    Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions.
    Tjandrawinata RR; Setiawati E; Yunaidi DA; Simanjuntak R; Santoso ID; Susanto LW
    Drug Des Devel Ther; 2013; 7():841-7. PubMed ID: 23990709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
    Kim YH; Kang P; Cho CK; Jung EH; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
    Arch Pharm Res; 2021 Jul; 44(7):713-724. PubMed ID: 34304363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure.
    Kassem I; Sanche S; Li J; Bonnefois G; Dubé MP; Rouleau JL; Tardif JC; White M; Turgeon J; Nekka F; de Denus S
    Clin Transl Sci; 2021 Jan; 14(1):194-203. PubMed ID: 32702160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of candesartan.
    Gleiter CH; Mörike KE
    Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.
    Cho CK; Park HJ; Kang P; Moon S; Lee YJ; Bae JW; Jang CG; Lee SY
    Arch Pharm Res; 2021 Dec; 44(12):1076-1090. PubMed ID: 34807366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.
    Whang SS; Cho CK; Jung EH; Kang P; Park HJ; Lee YJ; Choi CI; Bae JW; Kim HS; Jang CG; Lee SY
    Arch Pharm Res; 2022 Aug; 45(8):584-595. PubMed ID: 36028591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets.
    Zaid AN; Radwan A; Jaradat N; Mousa A; Ghazal N; Bustami R
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):621-626. PubMed ID: 29746726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.